Figure 2. Association of the Amyloid–Positron Emission Tomography Disclosure With Anxiety and Depression in Individuals With Subjective Cognitive Decline Plus Who Had Amyloid-Positive or Amyloid-Negative Results.

Hospital Anxiety and Depression scale (HADS) Anxiety and Depression scores (range 0-21, at least 15 indicates severe anxiety and/or depression symptoms). HADS was administered at baseline and after the amyloid-PET result disclosure. Dashed horizontal lines represent the threshold defining at least mild (HADS score ≥8) anxiety and/or depression symptoms. The prevalence of at least mild anxiety symptoms at follow-up was 30% (8 of 27 individuals) in individuals with amyloid-positive PET findings and 13% (10 of 78 individuals; χ² = 2.9, P = .09) in individuals with amyloid-negative PET findings. The prevalence of at least mild depression symptoms at follow-up was 11% (3 of 27 individuals) in individuals with amyloid-positive PET findings and 4% (3 of 78 individuals; χ² = 0.8, P = .36) in individuals with amyloid-negative PET findings.